Barclays PLC, a global financial services company, has increased its stake in Atara Biotherapeutics, Inc., a biotechnology firm specializing in the development of therapies for cancer and autoimmune diseases. According to the company’s recent filing with the Securities and Exchange Commission (SEC), Barclays PLC raised its position in Atara Biotherapeutics by 39.4% during the first quarter of this year.
As per the Form 13F filing, Barclays PLC now owns 400,563 shares of Atara Biotherapeutics, representing an additional 113,137 shares acquired during the reporting period. With this increase, Barclays PLC now holds approximately 0.41% ownership in the biotech company. Based on the most recent SEC filing, their investment in Atara Biotherapeutics has a market value of $1,162,000.
Atara Biotherapeutics is primarily focused on developing innovative therapies for patients suffering from solid tumors, hematologic cancers, and autoimmune diseases. The company’s leading product candidate is called Tab-cel (tabelecleucel), which is currently undergoing Phase 3 clinical trials.
Tab-cel is a T-cell immunotherapy treatment program specifically designed for patients affected by Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma—an uncommon form of cancer affecting the back of the nose and throat.
By investing in Atara Biotherapeutics, Barclays PLC has showcased its confidence in the potential of Tab-cel as a cutting-edge therapy for treating these challenging medical conditions. The increased position indicates their belief that Atara Biotherapeutics possesses significant value and growth potential within the biotechnology industry.
It is important to note that while Barclays PLC’s investment moves reflect positive sentiments towards Atara Biotherapeutics’ prospects as a biotech firm with promising therapeutic developments underway; it does not guarantee future performance or stock returns. Investors should exercise caution and carefully analyze all available information before making any investment decisions.
As of this report’s reference date in August 2023, investors and industry observers will likely continue to monitor Atara Biotherapeutics’ progress in its clinical trials with Tab-cel. The biotech company aims to provide innovative treatment options for patients suffering from challenging diseases, contributing to advancements in the field of biomedical research and patient care.
While further developments surround Atara Biotherapeutics are expected, it is essential to conduct thorough research and consult with financial professionals or experts before diving into investment opportunities. The dynamic nature of the biotech industry highlights the need for careful evaluation of investment risks and rewards.
In conclusion, Barclays PLC’s increased position in Atara Biotherapeutics demonstrates its growing confidence in the company’s potential as a developer of cutting-edge therapies in the biotechnology sector. With ongoing clinical trials for Tab-cel underway, Atara Biotherapeutics aims to address critical medical needs and improve patient outcomes. However, investors should remain vigilant and make informed decisions based on comprehensive research and analysis.
Atara Biotherapeutics, Inc.
Updated on: 06/12/2023
Debt to equity ratio: Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
8:00 PM (UTC)
Date:06 December, 2023
|Analyst / firm||Rating|
Uncertainty Surrounds Atara Biotherapeutics as Institutional Investors Shift Positions and Analyst Reports Offer Mixed Views
August 22, 2023 – Atara Biotherapeutics, Inc. has seen significant changes in its positions from institutional investors and has also been the focus of several research analyst reports. These developments have added to the perplexity surrounding the future of this biotechnology company.
Alpine Global Management LLC, M28 Capital Management LP, and Globeflex Capital L P are among the institutional investors that have acquired new positions in Atara Biotherapeutics. Alpine Global Management LLC invested $116,000 during the fourth quarter, while M28 Capital Management LP invested $1,441,000 during the same period. Globeflex Capital L P also made an investment worth $85,000 during this timeframe. On top of these acquisitions, SG Americas Securities LLC increased its position by 29.0% during the first quarter, owning 34,707 shares valued at $101,000 after purchasing an additional 7,792 shares. Envestnet Asset Management Inc. also lifted its position by 53.5% during the third quarter and now owns 16,045 shares worth $61,000 after acquiring an additional 5,589 shares.
Research analyst reports have provided further insight into Atara Biotherapeutics’ current state. HC Wainwright restated a “buy” rating and set a price target of $28.00 on June 14th. StockNews.com initiated coverage with a “sell” rating for the company on August 17th. Citigroup also dropped their price target from $2.00 to $1.40 in their report.
Atara Biotherapeutics focuses on developing therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its leading product is Tab-cel (tabelecleucel), which is currently undergoing Phase 3 clinical trials for the treatment of Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease and nasopharyngeal carcinoma.
In recent news, CEO Pascal Touchon sold 30,766 shares of the company’s stock on August 16th. The shares were sold at an average price of $1.65, totaling $50,763.90. Following this transaction, Touchon now owns 675,905 shares valued at $1,115,243.25. This sale was disclosed in a filing with the Securities and Exchange Commission (SEC). Insiders have collectively sold 61,915 shares of Atara Biotherapeutics’ stock over the last quarter, amounting to $102,303. Company insiders currently own 4.50% of the stock.
Trading for Atara Biotherapeutics opened at $1.41 on Tuesday. The company has witnessed a trading range between its 1-year lows of $1.25 and highs of $5.64. With a market capitalization of $142.55 million and a price-to-earnings ratio of -0.48, Atara Biotherapeutics continues to face uncertainty in both its financial performance and investor sentiment.
The firm also maintains a fifty-day moving average of $1.93 and a two-hundred-day moving average of $2.61.
In conclusion, Atara Biotherapeutics is experiencing significant changes in its positions from institutional investors while simultaneously being subjected to mixed research analyst reports. These developments highlight the ambiguity surrounding the company’s future prospects as it continues to develop therapies for cancer and autoimmune diseases in the United States.